CRA provided an expert opinion on damages in breach of contract litigation concerning the alleged improper grant of a patent sublicense. CRA identified the limited set of rights that would have been necessary to perform the allegedly improper development activity, based on a hypothetical negotiation between the parties, taking into account the willingness of the licensor to grant such a sublicense, and other market indicators of the value of such a sublicense.
Biosimilars: Economic Issues for IP Litigation
In July 2021, the U.S. Food and Drug Administration granted a determination of interchangeability to a biosimilar drug for the first time. This approval has...